<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lesson 10.8: Deprescribing Support: The Coach's Role in Medication Reduction</title>
    <style>
        /* Base & Reset */
        * {
            box-sizing: border-box;
        }

        body {
            font-family: Georgia, 'Times New Roman', serif;
            line-height: 1.8;
            color: #2d2d2d;
            background: #f8f6f3;
            margin: 0;
            padding: 0;
        }

        /* Main Container */
        .lesson-container {
            max-width: 860px;
            margin: 0 auto;
            padding: 40px 30px;
            background: #ffffff;
            min-height: 100vh;
            box-shadow: 0 0 60px rgba(0, 0, 0, 0.08);
        }

        /* Brand Header */
        .brand-header {
            text-align: center;
            padding-bottom: 30px;
            margin-bottom: 35px;
            border-bottom: 1px solid #eee;
        }

        .brand-logo {
            max-width: 220px;
            height: auto;
            margin-bottom: 5px;
        }

        /* Module Header - BLUE/TEAL theme for Medical Integration */
        .module-header {
            background: linear-gradient(135deg, #0f172a 0%, #334155 100%);
            padding: 35px 35px 30px;
            border-radius: 16px;
            margin-bottom: 30px;
            position: relative;
            overflow: hidden;
        }

        .module-header::before {
            content: '';
            position: absolute;
            top: 0;
            right: 0;
            width: 300px;
            height: 300px;
            background: radial-gradient(circle, rgba(255, 255, 255, 0.1) 0%, transparent 70%);
            transform: translate(100px, -100px);
        }

        .module-header::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 100%;
            height: 4px;
            background: linear-gradient(90deg, #B8860B, #D4A84B, #B8860B);
        }

        .module-label {
            margin: 0;
            font-size: 11px;
            color: rgba(255, 255, 255, 0.75);
            text-transform: uppercase;
            letter-spacing: 2.5px;
            font-weight: 500;
        }

        .lesson-title {
            margin: 10px 0 0 0;
            font-size: 28px;
            color: #ffffff;
            font-weight: 700;
            line-height: 1.3;
            position: relative;
        }

        .lesson-meta {
            display: flex;
            gap: 12px;
            margin-top: 20px;
            padding-top: 18px;
            border-top: 1px solid rgba(255, 255, 255, 0.15);
            flex-wrap: wrap;
        }

        .meta-item {
            display: flex;
            align-items: center;
            gap: 6px;
            font-size: 12px;
            color: rgba(255, 255, 255, 0.85);
            background: rgba(255, 255, 255, 0.1);
            padding: 5px 12px;
            border-radius: 4px;
        }

        /* Table of Contents */
        .toc-box {
            background: linear-gradient(135deg, #fafafa 0%, #f5f5f5 100%);
            border-radius: 14px;
            padding: 24px 28px;
            margin-bottom: 35px;
            border: 1px solid #e8e8e8;
        }

        .toc-box .box-label {
            font-weight: 600;
            color: #334155;
            margin: 0 0 18px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
            padding-bottom: 12px;
            border-bottom: 1px solid #e0e0e0;
        }

        .toc-list {
            list-style: none;
            margin: 0;
            padding: 0;
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 8px 24px;
        }

        .toc-list li {
            margin: 0;
        }

        .toc-list a {
            display: flex;
            align-items: center;
            padding: 8px 12px;
            color: #555;
            text-decoration: none;
            font-size: 14px;
            border-radius: 6px;
            transition: all 0.2s ease;
        }

        .toc-list a:hover {
            background: white;
            color: #334155;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.06);
        }

        .toc-list .section-num {
            display: inline-flex;
            align-items: center;
            justify-content: center;
            width: 26px;
            height: 26px;
            background: #334155;
            color: white;
            font-weight: 600;
            font-size: 11px;
            border-radius: 6px;
            margin-right: 12px;
            flex-shrink: 0;
        }

        /* Learning Objectives */
        .objectives-box {
            background: #f8fafc;
            border: 2px solid #334155;
            border-radius: 14px;
            padding: 30px 35px;
            margin-bottom: 40px;
        }

        .objectives-box .box-label {
            font-weight: 600;
            color: #334155;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .objectives-box .box-label::before {
            content: 'ðŸŽ¯';
            font-size: 18px;
        }

        .objectives-box ul {
            margin: 0;
            padding-left: 22px;
        }

        .objectives-box li {
            margin-bottom: 14px;
            font-size: 16px;
            line-height: 1.7;
        }

        /* Key Terms Box */
        .key-terms-box {
            background: linear-gradient(135deg, #f1f5f9 0%, #e2e8f0 100%);
            border-radius: 14px;
            padding: 28px 30px;
            margin: 40px 0;
            border: 1px solid #cbd5e1;
        }

        .key-terms-box .box-label {
            font-weight: 600;
            color: #1e293b;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
        }

        .terms-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(280px, 1fr));
            gap: 16px;
        }

        .term-item {
            background: white;
            padding: 16px 18px;
            border-radius: 10px;
            border-left: 4px solid #334155;
        }

        .term-item .term {
            font-weight: 700;
            color: #1e293b;
            font-size: 15px;
            margin: 0 0 6px 0;
        }

        .term-item .definition {
            font-size: 14px;
            color: #555;
            margin: 0;
            line-height: 1.6;
        }

        /* Section Headings */
        h2 {
            font-size: 24px;
            color: #1e293b;
            margin: 50px 0 20px 0;
            font-weight: 600;
            position: relative;
            padding-bottom: 12px;
        }

        h2::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 3px;
            background: #B8860B;
        }

        /* Paragraphs */
        p {
            font-size: 17px;
            margin-bottom: 20px;
            color: #333;
        }

        /* Highlights */
        .highlight {
            background: linear-gradient(180deg, transparent 60%, #e2e8f0 60%);
            padding: 0 4px;
            font-weight: 600;
            color: #1e293b;
        }

        /* Welcome/Intro Box */
        .welcome-box {
            background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);
            padding: 30px 35px;
            border-radius: 14px;
            margin-bottom: 40px;
            border: 1px solid #e2e8f0;
        }

        .welcome-box h3 {
            margin: 0 0 15px 0;
            font-size: 20px;
            color: #1e293b;
            font-weight: 600;
        }

        /* Case Study Box */
        .case-study {
            background: linear-gradient(135deg, #f8f9fb 0%, #f0f2f5 100%);
            border-radius: 16px;
            padding: 0;
            margin: 40px 0;
            overflow: hidden;
            box-shadow: 0 4px 20px rgba(0, 0, 0, 0.06);
        }

        .case-study-header {
            background: linear-gradient(135deg, #1e293b 0%, #334155 100%);
            padding: 20px 30px;
            display: flex;
            align-items: center;
            gap: 15px;
        }

        .case-study-icon {
            width: 45px;
            height: 45px;
            background: rgba(255, 255, 255, 0.15);
            border-radius: 10px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 22px;
        }

        .case-study-header .box-label {
            font-weight: 600;
            color: #ffffff;
            margin: 0;
            font-size: 16px;
        }

        .case-study-content {
            padding: 28px 30px;
        }

        .patient-profile {
            display: flex;
            align-items: center;
            gap: 18px;
            padding: 18px 22px;
            background: white;
            border-radius: 12px;
            margin-bottom: 20px;
            border: 1px solid #e5e5e5;
        }

        .patient-avatar {
            width: 55px;
            height: 55px;
            background: linear-gradient(135deg, #334155, #1e293b);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 24px;
            flex-shrink: 0;
        }

        /* Statistics Box */
        .stats-box {
            background: linear-gradient(135deg, #1e293b 0%, #334155 100%);
            padding: 40px;
            border-radius: 16px;
            margin: 35px 0;
            position: relative;
            overflow: hidden;
        }

        .stats-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(140px, 1fr));
            gap: 25px;
            position: relative;
            z-index: 1;
        }

        .stat-item {
            text-align: center;
        }

        .stat-number {
            font-size: 42px;
            font-weight: 700;
            color: white;
            line-height: 1;
            margin-bottom: 8px;
        }

        .stat-label {
            font-size: 11px;
            color: rgba(255, 255, 255, 0.85);
            text-transform: uppercase;
            letter-spacing: 1px;
        }

        /* Comparison Table */
        .data-table-container {
            overflow-x: auto;
            margin: 30px 0;
            border-radius: 12px;
            border: 1px solid #e2e8f0;
        }

        table {
            width: 100%;
            border-collapse: collapse;
            font-size: 15px;
            background: white;
        }

        th {
            background: #f1f5f9;
            color: #1e293b;
            font-weight: 700;
            text-align: left;
            padding: 15px;
            border-bottom: 2px solid #e2e8f0;
        }

        td {
            padding: 15px;
            border-bottom: 1px solid #f1f5f9;
            vertical-align: top;
        }

        /* Check Understanding Box */
        .check-understanding {
            background: linear-gradient(135deg, #fdfbf7 0%, #f9f5ed 100%);
            border: 2px solid #B8860B;
            border-radius: 16px;
            padding: 32px;
            margin: 45px 0;
        }

        .question-item {
            background: white;
            border-radius: 12px;
            padding: 22px 24px;
            margin-bottom: 16px;
            border: 1px solid #e8e4dc;
            position: relative;
        }

        .reveal-btn {
            background: #334155;
            color: white;
            border: none;
            padding: 10px 20px;
            border-radius: 8px;
            font-size: 14px;
            cursor: pointer;
            transition: background 0.2s ease;
        }

        .answer-text {
            display: none;
            font-size: 14px;
            color: #1e293b;
            margin: 14px 0 0 0;
            padding: 14px;
            background: #f1f5f9;
            border-radius: 8px;
        }

        .answer-text.show {
            display: block;
        }

        /* Takeaways & References */
        .takeaways-box {
            background: #f1f5f9;
            padding: 25px;
            margin-top: 35px;
            border-radius: 12px;
            border: 1px solid #cbd5e1;
        }

        .references-box {
            margin-top: 40px;
            padding-top: 25px;
            border-top: 1px solid #eee;
            font-size: 14px;
            color: #666;
        }

        .references-box h4 {
            color: #1e293b;
            margin-bottom: 15px;
        }

        .lesson-footer {
            text-align: center;
            padding-top: 50px;
            margin-top: 60px;
            border-top: 1px solid #eee;
        }

        .brand-text {
            color: #334155;
            font-weight: 600;
        }
    </style>
</head>

<body>
    <div class="lesson-container">
        <div class="brand-header">
            <img src="https://accredipro.com/wp-content/uploads/2023/05/AccrediPro-Logo-Standard-1.png" alt="AccrediPro Academy" class="brand-logo">
        </div>

        <header class="module-header">
            <p class="module-label">Module 10: Pharmacology & Medical Integration</p>
            <h1 class="lesson-title">Lesson 10.8: Deprescribing Support: The Coach's Role in Medication Reduction</h1>
            <div class="lesson-meta">
                <span class="meta-item">35 min read</span>
                <span class="meta-item">Lesson 8 of 10</span>
            </div>
        </header>

        <div class="toc-box">
            <p class="box-label">In This Lesson</p>
            <ul class="toc-list">
                <li><a href="#section1"><span class="section-num">1</span>Defining Deprescribing</a></li>
                <li><a href="#section2"><span class="section-num">2</span>The Coachâ€™s Scope of Practice</a></li>
                <li><a href="#section3"><span class="section-num">3</span>Identifying Candidates</a></li>
                <li><a href="#section4"><span class="section-num">4</span>The STABLE Method Integration</a></li>
                <li><a href="#section5"><span class="section-num">5</span>Communicating with Physicians</a></li>
                <li><a href="#section6"><span class="section-num">6</span>Safety & Monitoring</a></li>
            </ul>
        </div>

        <div class="objectives-box">
            <p class="box-label">Learning Objectives</p>
            <ul>
                <li>Define deprescribing and its clinical significance in Type 2 Diabetes remission.</li>
                <li>Establish clear boundaries for the coach's role in the medication reduction process.</li>
                <li>Identify clinical "red flags" and "green flags" for medication tapering.</li>
                <li>Utilize CGM data to advocate for client safety during lifestyle-induced blood sugar drops.</li>
                <li>Develop a collaborative communication strategy for the client-coach-physician triad.</li>
            </ul>
        </div>

        <div class="welcome-box">
            <h3>The Ultimate Goal of Metabolic Coaching</h3>
            <p>One of the most rewarding moments for a Diabetes & Blood Sugar Coach is seeing a client successfully reduce or eliminate their dependence on glucose-lowering medications. However, this transition is also the most high-risk period of the coaching journey. As the <span class="highlight">STABLE Methodâ„¢</span> begins to take effectâ€”improving insulin sensitivity and reducing glycemic variabilityâ€”the medications that were once necessary can become dangerous. This lesson teaches you how to navigate the delicate balance of supporting medical reduction while maintaining absolute clinical safety.</p>
        </div>

        <div class="key-terms-box">
            <p class="box-label">ðŸ”¬ Key Terms to Know</p>
            <div class="terms-grid">
                <div class="term-item">
                    <p class="term">Deprescribing</p>
                    <p class="definition">The planned and supervised process of dose reduction or stopping of medication that might be causing harm or no longer be of benefit.</p>
                </div>
                <div class="term-item">
                    <p class="term">Therapeutic Inertia</p>
                    <p class="definition">The failure of healthcare providers to initiate or intensify therapy when therapeutic goals are not met, or conversely, to de-escalate when goals are exceeded.</p>
                </div>
                <div class="term-item">
                    <p class="term">Hypoglycemia Unawareness</p>
                    <p class="definition">A complication where a client no longer experiences the early warning signs of low blood sugar, increasing the risk of severe neuroglycopenia.</p>
                </div>
                <div class="term-item">
                    <p class="term">Rebound Hyperglycemia</p>
                    <p class="definition">An elevation in blood glucose levels following a period of hypoglycemia or a rapid reduction in medication dosage.</p>
                </div>
            </div>
        </div>

        <h2 id="section1">Defining Deprescribing in Diabetes Care</h2>
        <p>In the traditional medical model, Type 2 Diabetes (T2D) is often treated as a progressive, lifelong disease requiring ever-increasing doses of medication. However, modern clinical trials like the <span class="highlight">DiRECT study</span> and the <span class="highlight">Virta Health 2-year trial</span> have proven that T2D can be put into remission through intensive lifestyle intervention. </p>
        
        <p>Deprescribing is not merely "stopping pills." It is a clinical intervention designed to improve quality of life by reducing polypharmacy, side effects, and the risk of severe hypoglycemia. For a coach, deprescribing support means providing the physiological data (via CGM) and lifestyle consistency that allows a physician to make safe, informed decisions about reducing a client's pharmaceutical load.</p>

        <div class="stats-box">
            <div class="stats-grid">
                <div class="stat-item">
                    <div class="stat-number">67%</div>
                    <div class="stat-label">Virta Study: Meds Eliminated</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">46%</div>
                    <div class="stat-label">DiRECT Trial: Remission Rate</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">3.5x</div>
                    <div class="stat-label">Risk of Hypos w/ Sulfonylureas</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">0.5%</div>
                    <div class="stat-label">A1c drop per 1kg loss</div>
                </div>
            </div>
        </div>

        <h2 id="section2">The Coachâ€™s Scope of Practice: The Hard Line</h2>
        <p>Before we proceed, we must establish the "Golden Rule" of medical integration: <span class="highlight">Coaches never advise a client to change, reduce, or stop a medication.</span> Doing so is practicing medicine without a license and poses a significant legal and safety risk.</p>
        
        <p>Instead, the coach acts as a <strong>Decision Support Specialist</strong>. You provide the evidence (tracking), the mechanism (lifestyle), and the education (understanding side effects) that empowers the client to have a productive conversation with their doctor. Your role is to bridge the gap between the client's daily data and the doctor's clinical oversight.</p>

        <div class="data-table-container">
            <table>
                <thead>
                    <tr>
                        <th>Action</th>
                        <th>Coach's Role</th>
                        <th>Physician's Role</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Dose Adjustment</strong></td>
                        <td>Identify patterns of hypoglycemia in CGM data.</td>
                        <td>Calculate and order the new dosage or taper schedule.</td>
                    </tr>
                    <tr>
                        <td><strong>Medication Choice</strong></td>
                        <td>Educate on mechanism of action and common lifestyle interactions.</td>
                        <td>Select the appropriate agent based on comorbidities and labs.</td>
                    </tr>
                    <tr>
                        <td><strong>Safety Monitoring</strong></td>
                        <td>Daily check-ins on symptoms and "Time in Range."</td>
                        <td>Order blood work (A1c, C-peptide) to confirm stability.</td>
                    </tr>
                    <tr>
                        <td><strong>Stopping Meds</strong></td>
                        <td>Document 14+ days of glycemic stability without spikes.</td>
                        <td>Officially discontinue the medication in the medical record.</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <h2 id="section3">Identifying Candidates for Medication Reduction</h2>
        <p>Not every client is a candidate for immediate deprescribing. We look for specific clinical "Green Flags" that indicate the body is regaining metabolic autonomy. According to consensus reports from the American Diabetes Association (ADA), candidates for de-intensification include:</p>
        
        <ul>
            <li><strong>A1c Levels:</strong> Consistently below 6.5% (or even 6.0% for some practitioners) on current medication.</li>
            <li><strong>Hypoglycemia:</strong> Any instance of blood sugar < 70 mg/dL, especially if recurrent or nocturnal.</li>
            <li><strong>Weight Loss:</strong> A loss of 5-10% of total body weight often significantly increases insulin sensitivity.</li>
            <li><strong>Lifestyle Change:</strong> Successful implementation of the <span class="highlight">Evolutionary-Based Nutrition (E)</span> and <span class="highlight">Active Sensitization (A)</span> phases of the STABLE Method.</li>
        </ul>

        <div class="case-study">
            <div class="case-study-header">
                <div class="case-study-icon">ðŸ‘¤</div>
                <div>
                    <p class="box-label">Case Study: Robertâ€™s Sulfonylurea Risk</p>
                    <p style="color: rgba(255,255,255,0.8); margin:0; font-size:12px;">Hypoglycemia during Active Sensitization</p>
                </div>
            </div>
            <div class="case-study-content">
                <div class="patient-profile">
                    <div class="patient-avatar">R</div>
                    <div class="patient-info">
                        <h4>Robert, 58</h4>
                        <p>Type 2 Diabetes (7 years), Metformin 2000mg, Glipizide (Sulfonylurea) 10mg.</p>
                    </div>
                </div>
                <p><strong>The Challenge:</strong> Robert began the <span class="highlight">Active Sensitization (A)</span> phase of the STABLE Method, adding 30 minutes of resistance training three times per week. Within four days, his CGM showed 3:00 AM glucose levels of 58 mg/dL.</p>
                <p><strong>Intervention:</strong> As his coach, you did not tell him to stop the Glipizide. Instead, you helped him download his CGM "Ambulatory Glucose Profile" (AGP) report. You coached him to send this report to his doctor with the message: <em>"I am experiencing nocturnal hypoglycemia since starting my new exercise routine. Please advise on adjusting my Glipizide."</em></p>
                <p><strong>Outcome:</strong> The physician immediately discontinued the Glipizide. Robertâ€™s fasting glucose stabilized at 95 mg/dL without the lows, and his "Time in Range" increased from 72% to 98%.</p>
            </div>
        </div>

        <h2 id="section4">Integrating the STABLE Methodâ„¢ into Deprescribing</h2>
        <p>The <span class="highlight">STABLE Methodâ„¢</span> provides the physiological framework that makes deprescribing possible. Each letter plays a role in reducing the need for exogenous glucose control:</p>
        
        <div class="principle-card">
            <p class="principle-title">S: Stabilization of Glycemic Variability</p>
            <p class="principle-text">By "flattening the curve," we reduce the need for bolus insulin or secretagogues (like Sulfonylureas) that are designed to combat post-meal spikes.</p>
        </div>
        
        <div class="principle-card">
            <p class="principle-title">A: Active Sensitization</p>
            <p class="principle-text">Resistance training increases GLUT4 translocation. As the muscles become "glucose sponges," the required dose of insulin or Metformin naturally decreases.</p>
        </div>
        
        <div class="principle-card">
            <p class="principle-title">E: Evolutionary-Based Nutrition</p>
            <p class="principle-text">Prioritizing fiber and protein-to-carb ratios triggers natural GLP-1 production, potentially allowing for the reduction of synthetic GLP-1 agonists over time.</p>
        </div>

        <h2 id="section5">The Communication Triad: Coach, Client, Physician</h2>
        <p>A primary barrier to deprescribing is <span class="highlight">Therapeutic Inertia</span>. Doctors are busy and often fear the "rebound" effect if meds are removed. Your job is to help the client present a "Data-Driven Case" for reduction. A successful communication package includes:</p>
        
        <ol class="content-list">
            <li><strong>14-Day CGM Report:</strong> Showing average glucose, GMI (estimated A1c), and Time in Range.</li>
            <li><strong>Symptom Log:</strong> Highlighting episodes of dizziness, sweatiness, or confusion (hypoglycemia).</li>
            <li><strong>Lifestyle Summary:</strong> "I have consistently maintained a < 50g net carb intake and 150 minutes of zone 2/resistance training for 4 weeks."</li>
            <li><strong>Specific Ask:</strong> "Based on my consistent readings below 90 mg/dL, are we at a point where we can trial a lower dose of [Medication]?"</li>
        </ol>

        <h2 id="section6">Safety & Monitoring During the Transition</h2>
        <p>When a medication is reduced, the body undergoes a period of re-adaptation. As a coach, you must be hyper-vigilant during the 72 hours following a dose change. Watch for the following:</p>
        
        <p><strong>The Rebound Effect:</strong> Sometimes, the liver over-compensates when a medication (especially insulin) is reduced, causing a temporary spike in fasting glucose. Use <span class="highlight">Lifestyle & Circadian Modulation (L)</span>â€”specifically sleep hygieneâ€”to dampen this cortisol-driven response.</p>
        
        <p><strong>SGLT2i Caution:</strong> If a client is reducing an SGLT2 inhibitor (e.g., Jardiance), they must be monitored for signs of Euglycemic Ketoacidosis (nausea, abdominal pain, fruity breath) even if blood sugar looks "normal." This is a medical emergency.</p>

        <div class="check-understanding">
            <p class="box-label">Check Your Understanding</p>
            <p class="box-subtitle">Test your knowledge on the coach's role in deprescribing.</p>
            
            <div class="question-item">
                <div class="question-number">1</div>
                <p class="question-text">A client's CGM shows frequent readings of 65 mg/dL after their morning Metformin dose. What is the most appropriate coaching response?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">Instruct the client to document these readings and contact their doctor immediately to discuss a dose reduction. Metformin rarely causes hypos alone, but in combination with lifestyle changes or other meds, it can contribute. Never tell them to skip the dose yourself.</div>
            </div>

            <div class="question-item">
                <div class="question-number">2</div>
                <p class="question-text">Why is the "A" (Active Sensitization) phase of the STABLE Method a critical time for deprescribing support?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">Exercise increases non-insulin-mediated glucose uptake. If the client remains on a high dose of insulin or secretagogues while increasing muscle glucose uptake, the risk of severe hypoglycemia increases significantly.</div>
            </div>
        </div>

        <div class="takeaways-box">
            <p class="box-label">Key Takeaways</p>
            <ul>
                <li>Deprescribing is a clinical process; the coach provides the <strong>supporting data</strong> but never the <strong>medical order</strong>.</li>
                <li>Hypoglycemia (blood sugar < 70 mg/dL) is the primary "Green Flag" for immediate medical consultation regarding dose reduction.</li>
                <li>The STABLE Methodâ„¢ facilitates deprescribing by improving insulin sensitivity and reducing the need for exogenous glucose management.</li>
                <li>Use CGM reports (AGP) as the objective "bridge" for communication between the client and their physician.</li>
                <li>Be alert for "rebound" effects or rare complications like euglycemic ketoacidosis during the tapering phase.</li>
            </ul>
        </div>

        <div class="references-box">
            <h4>References & Further Reading</h4>
            <ul>
                <li>Hallberg, S. J., et al. (2019). "Long-term outcomes of a multi-arm diabetes reversal trial." <i>Frontiers in Endocrinology</i>.</li>
                <li>Lean, M. E., et al. (2018). "Primary care-led weight management for remission of type 2 diabetes (DiRECT)." <i>The Lancet</i>.</li>
                <li>Scott, I. A., et al. (2021). "Deprescribing in Type 2 Diabetes: A Review of the Evidence." <i>Medical Journal of Australia</i>.</li>
                <li>Taylor, R., et al. (2021). "Remission of Type 2 Diabetes: An ADA/EASD/Diabetes UK Consensus Report." <i>Diabetes Care</i>.</li>
                <li>Reeve, E., et al. (2014). "Patient perspectives on deprescribing: a systematic review." <i>Therapeutic Advances in Drug Safety</i>.</li>
                <li>Davies, M. J., et al. (2022). "Management of Hyperglycemia in Type 2 Diabetes: A Consensus Report by the ADA and EASD." <i>Diabetes Care</i>.</li>
            </ul>
        </div>

        <footer class="lesson-footer">
            <img src="https://accredipro.com/wp-content/uploads/2023/05/AccrediPro-Logo-Standard-1.png" alt="AccrediPro Academy" class="footer-logo">
            <p class="brand">AccrediPro Academy: Diabetes & Blood Sugar Coach Certification</p>
            <p class="copyright">&copy; 2024 AccrediPro. All Rights Reserved. For Professional Use Only.</p>
        </footer>
    </div>
</body>

</html>